Nanobiotix

Nanobiotix on fru.dev

• Frontier tech

Nanobiotix across fru.dev: timeline

1. 2026-05-21 Nanobiotix: Public follow-on offering $100M (Emerging)
2. 2026-05-21 Nanobiotix prices an oversubscribed EUR 85M global offering (Emerging)
3. 2026-03-30 First randomized Phase 2 data for JNJ-1900 in stage 3 lung cancer (Emerging)
4. 2025-11-24 Nanobiotix: Royalty financing $71M (Emerging)
5. 2025-07-07 European regulators reclassify NBTXR3 from device to medicinal product (Emerging)
6. 2025-03-17 Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnson (Emerging)
7. 2024-05-14 FDA accepts protocol for Phase 2 NBTXR3 study in stage 3 lung cancer (Emerging)

Sources

• emerging.fru.dev/companies/nanobiotix